Orchid Pharma zooms on signing licensing and supply agreement with Pharmasyntez
Orchid Pharma is currently trading at Rs. 1023.40, up by 96.75 points or 10.44% from its previous closing of Rs. 926.65 on the BSE.
The scrip opened at Rs. 966.65 and has touched a high and low of Rs. 1,047.50 and Rs. 966.65 respectively. So far 498 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1096.40 on 16-Jun-2026 and a 52 week low of Rs. 471.30 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 1,047.50 and Rs. 920.00 respectively. The current market cap of the company is Rs. 4699.89 crore.
The promoters holding in the company stood at 69.84%, while Institutions and Non-Institutions held 21.12% and 9.05% respectively.
Orchid Pharma (Orchid) and Pharmasyntez JSC (Pharmasyntez) have entered into a licensing and supply agreement for Exblifep (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gramnegative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation.
Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by ESBL-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals.
Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. The partnership represents a potential opportunity of around $178 million over the first 10 years, reflecting the scale of unmet clinical need and the significant hospital procurement volumes in the Russian market.
